Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer

B. E. P. J. Vriens,Ingeborg J.H. Vriens,Maureen J. Aarts,S van Gastel,F van den Berkmortel,Tineke J. Smilde,L.J.C. van Warmerdam,D.J. van Spronsen,Pgm Peer,M. de Boer,Vivianne C. G. Tjan-Heijnen

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer

2017

B. E. P. J. Vriens
Ingeborg J.H. Vriens
Maureen J. Aarts
S van Gastel
F van den Berkmortel
Tineke J. Smilde
L.J.C. van Warmerdam
D.J. van Spronsen
Pgm Peer
M. de Boer
Vivianne C. G. Tjan-Heijnen

Purpose The INTENS study was designed to determine whether delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients.

Keywords:

Breast cancer
Cancer research
Doxorubicin/Cyclophosphamide
Anthracycline
Doxorubicin
Chemotherapy
Cyclophosphamide
Oncology
Internal medicine
Metastatic breast cancer
Docetaxel
Medicine
Neoadjuvant therapy
Hazard ratio
combination chemotherapy
Cumulative dose

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations